Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-01-01 Oestrogens and HRT
Information is providided on the available preparations. The choice of preparation (tablet,
patch, gel) remains with the prescriber, taking into consideration patient preference and cost effectiveness.
| Combined continuous HRT tablet Femoston Conti |
|
Formulary
|
| Tablets Estradiol 1mg/Dygesterone 5mg Combined therapy for women with uterus or endometriosis post hysterectomy |
 MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
| Combined cyclical HRT tablet |
|
Formulary
|
|
MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
|
| Estradiol / progesterone Bijuve |
|
Formulary
|
Bijuve® is an alternative when other HRT treatments have not been tolerated or when Femoston-Conti® is being considered OR |
|
LSCMMG: Estradiol / micronised progesterone MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
| Oestrogen only HRT implant Estradiol |
|
Formulary
|
Implant 50mg For patients who cannot tolerate other formulations. |
|
MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
| Oestrogen only HRT tablet Elleste-Solo |
|
Formulary
|
Tablets 1mg, 2mg |
|
MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
|
| Tibolone Livial® |
|
Formulary
|
|
MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
|
Links
- BMS: BMS statement in response to the publication of the updated NICE Menopause guideline (NG23)
- LSCMMG: Estradiol / micronised progesterone
LSCMMG: Trans Female Gender Dysphoria Information Sheet- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- NICE NG23: Menopause: identification and management
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women